Karuna Therapeutics, Inc.

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Bullish Continuation in '24? 3 Market Areas to Watch

Cramer names biopharma companies to watch as industry mergers start to pile up

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Yes Virginia, There Is a Santa Claus Rally

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Nano Dimension Buys Stratasys, Bristol Myers's Shopping Spree, Apple Gets a ‘No'

Bristol-Myers buying Karuna signals a biotech boom ahead: Jefferies

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.

Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal

Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook

Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal

Biotech stocks set for a rebound in 2024, analysts say

Shareholder Alert: Ademi LLP investigates whether Karuna Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol-Myers

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

A Major Acquisition and Other News Ahead of the Holiday Weekend

Karuna Stock Soars On Bristol Myers' $14 Billion Takeover

Bristol Myers to buy Karuna Therapeutics for $14B